Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.
Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients, while enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.